Cellipont
Biotechnology · Regenerative Medicine
Overview
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP manufacturing.
Funding and backers
Backers
1
OrbiMed
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Constellation® is an automated cell therapy manufacturing platform that enables scalable, flexible production without therapy redevelopment…
Avigen develops cellular avidity tools for immunotherapy and cell therapy R&D, helping identify potent and safe lead drug candidates faster.
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Our CELLfinity platform is delivering safe in vivo cell & gene therapies that is based on our proprietary EXiVO approach, without…
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies. Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from early development through commercial supply.
RESEARCH TRIANGLE PARK, NC and THE WOODLANDS, TX - Sept. 17, 2026- Kincell Bio and Cellipont Bioservices today announced the completion of their merger to form Kincellis Advanced Therapies (Kincellis), a U.S.-based contract development and manufacturing o
Read more
Report
Cellipont Bioservices and Xiogenix Publish New White Paper on Automated Fill-Finish for Scalable Cell Therapy Manufacturing
The WOODLANDS, Texas and Muskego, Wisconsin. - September 9, 2026/ Cision / - Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in cell and gene therapy downstream process a
Read more
Report
Cellipont Bioservices and Xiogenix Publish New White Paper on Automated Fill-Finish for Scalable Cell Therapy Manufacturing
Read more
Report
Cellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026
THE WOODLANDS, Texas - September 3, 2026 / Cision / - Cellipont Bioservices, a cell therapy contract development and manufacturing organization, today announced that its Texas facility has supported six client projects to date that are expected to reach I
Read more
Report
Cellipont Bioservices
Cellipont Bioservices, a cell therapy contract development and manufacturing organization, today announced that its Texas facility has supported six client projects to date that are expected to reach Investigational New Drug application submission in 2026
Read more
Report
Cellipont Bioservices Celebrates Release of 100th GMP Batch
/PRNewswire/ -- Cellipont Bioservices, a cell therapy contract development and manufacturing organization, today announced the successful release of its 100th...
Read more
Report
Cellipont Bioservices Celebrates Release of 100th GMP Batch
Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility THE WOODLANDS, Texas - July 28, 2026/ Cision / - Cellipont Bioservices, a cell therapy contract development and manufactur
Read more
Report
Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development
Milpitas, CA and The Woodlands, TX - March 24, 2026 / Cision / - Applied StemCell, Inc. ("ASC"), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract develop
Read more
Report
Cellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors
The WOODLANDS, Texas and HUMMELSTOWN, Pa- March 16, 2026/ Cision / - Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biote
Read more
Report
Show more news